IL1R1 and COVID-19: Interventions targeting COVID-19 among PICU patients included: hydroxychloroquine 63%, azithromycin 37%, corticosteroids 30%, remdesivir 27%, tocilizumab (anti-IL6R) 13%, anakinra (anti-IL1R) 13%, and intravenous immunoglobulin (IVIg) 10%.